logo
Plus   Neg
Share
Email

NVO : FDA Oks Ozempic For CV Risk Reduction In Type 2 Diabetes & Established CVD

Novo Nordisk said that the U.S. Food and Drug Administration has approved a label expansion based on a supplemental New Drug Application or sNDA for Ozempic for the indication of reducing the risk of major adverse cardiovascular events or MACE including cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes and established cardiovascular disease or CVD.

The approval was based on the SUSTAIN 6 cardiovascular outcomes trial (CVOT), which demonstrated that Ozempic statistically significantly reduced the risk of CV death, non-fatal heart attack or non-fatal stroke by 26% versus placebo, when added to standard of care in people with type 2 diabetes with increased CV risk.

The FDA also updated the Rybelsus label to include additional information from the PIONEER 6 CVOT demonstrating CV safety.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Many retailers including Target, Walmart and CVS announced temporary store closures in various regions across the United States following violence and looting amid the unrest related to the death of George Floyd. The street protests, some peaceful and some violent, erupted across the nation after Floyd was mercilessly killed by Minnesota police. Nestle USA, a division of Swiss food major Nestlé, announced the recall of certain Lean Cuisine Fettuccini Alfredo products citing misbranding and the presence of an undeclared allergen. According to the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS, the recall involves approximately 29,002 pounds of chicken products. Apple chief executive officer Tim Cook condemned the killing of an unarmed black man, George Floyd, and called for the creation of a "better, more just world for everyone," according to reports citing a memo to employees.
RELATED NEWS
Follow RTT